Sells 3,617 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Great West Life Assurance Co. Can lowered its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 2.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 133,150 shares of the medical research company’s stock after selling 3,617 shares during the quarter. Great West Life Assurance Co. Can owned 0.12% of NeoGenomics worth $4,123,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. First Trust Advisors LP increased its stake in shares of NeoGenomics by 189.2% during the 1st quarter. First Trust Advisors LP now owns 99,356 shares of the medical research company’s stock worth $2,743,000 after purchasing an additional 65,003 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of NeoGenomics by 16.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,632 shares of the medical research company’s stock worth $266,000 after acquiring an additional 1,334 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in shares of NeoGenomics by 683.5% in the first quarter. Oppenheimer Asset Management Inc. now owns 7,334 shares of the medical research company’s stock worth $202,000 after acquiring an additional 6,398 shares during the period. Mackay Shields LLC purchased a new position in shares of NeoGenomics in the first quarter valued at $1,005,000. Finally, Swiss National Bank raised its stake in shares of NeoGenomics by 1.9% during the 1st quarter. Swiss National Bank now owns 192,400 shares of the medical research company’s stock valued at $5,312,000 after purchasing an additional 3,500 shares during the period. 91.67% of the stock is currently owned by hedge funds and other institutional investors.

In other NeoGenomics news, insider George Cardoza sold 82,500 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $39.35, for a total transaction of $3,246,375.00. Following the completion of the transaction, the insider now owns 433,402 shares of the company’s stock, valued at $17,054,368.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Robert J. Shovlin sold 81,356 shares of the business’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $38.17, for a total transaction of $3,105,358.52. Following the sale, the insider now owns 212,902 shares in the company, valued at approximately $8,126,469.34. The disclosure for this sale can be found here. Insiders have sold 247,273 shares of company stock worth $9,498,701 in the last quarter. 6.50% of the stock is owned by corporate insiders.

Shares of NeoGenomics stock opened at $35.83 on Monday. The stock has a market capitalization of $3.86 billion, a P/E ratio of -716.60 and a beta of 0.80. NeoGenomics, Inc. has a one year low of $18.52 and a one year high of $41.03. The company has a debt-to-equity ratio of 0.25, a current ratio of 6.79 and a quick ratio of 6.44. The business’s 50 day simple moving average is $38.15 and its two-hundred day simple moving average is $31.31.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.06. The firm had revenue of $86.90 million for the quarter, compared to analyst estimates of $86.55 million. NeoGenomics had a positive return on equity of 0.73% and a negative net margin of 1.33%. The business’s quarterly revenue was down 14.6% compared to the same quarter last year. During the same period last year, the company earned $0.07 EPS. Sell-side analysts expect that NeoGenomics, Inc. will post -0.01 earnings per share for the current fiscal year.

NEO has been the topic of a number of recent analyst reports. Morgan Stanley assumed coverage on shares of NeoGenomics in a report on Wednesday, September 9th. They issued an “overweight” rating and a $46.00 price target on the stock. Benchmark raised their price target on shares of NeoGenomics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Zacks Investment Research cut shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 7th. Bank of America initiated coverage on NeoGenomics in a research report on Thursday, June 25th. They issued a “buy” rating and a $34.00 price objective on the stock. Finally, Needham & Company LLC boosted their target price on NeoGenomics from $33.00 to $39.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Three analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. NeoGenomics currently has a consensus rating of “Buy” and a consensus target price of $37.50.

NeoGenomics Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

See Also: Short Selling – Explanation For Shorting Stocks

Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO).

Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.

Original Source